mAbs from mammalian cells

Cytos Biotechnology AG has developed an antibody platform that employs mammalian cell display to isolate high-affinity human antibodies faster-and possibly with greater diversity-than phage display.¹The company already has identified a possible development candidate for nicotine addiction through a single round of screening on a modified version of its cloning platform.

Since publishing those results in the Proceedings of the National Academy of Sciences, the research team-led by senior scientist Roger Beerli-has used the platform to isolate several antibodies against HBV and the influenza A virus and has those mAbs in preclinical development...